Skip to content

Contact +44 (0) 20 7060 7474 email us

Company Information

Takeda Pharmaceutical Co. Ltd: PharmaVitae Profile

 

Publication Date February 2009
Publisher Datamonitor
Product Type Report
Pages 152
ISBN Number not applicable
Product Code DAT01705

Price

£1,965.00
approximately: $3,010 | €2,189

pdf

Buy Now

print £3,060 ($4,687 | €3,410)

Buy Now

Order above formats by FAX

Order by Fax

Summary

Introduction
This analysis examines the historical and forecast performance for Takeda in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope



Highlights



Reasons to Purchase


  • Benchmark Takeda's performance against key rivals in the prescription pharmaceutical sector
  • Determine the impact of blockbuster patent expiries on the long-term financial performance of Japan's number one pharmaceutical company
  • Scope out the various strategies being implemented by cash-rich Takeda as it looks become a leading player in the fast-growth oncology space

    • Contents

    • TABLE OF CONTENTS
    • CHAPTER 1 ABOUT THIS PROFILE
      • Executive summary
      • Quarterly news update
      • Company introduction
      • Company sales
      • Company financials
      • Key products and competitors
      • Data sourcing
      • Sales data
      • Analyst consensus
    • CHAPTER 2 EXECUTIVE SUMMARY
      • Key findings
      • Prescription pharmaceutical sales performance, 2001-13
      • Financial performance, 2001-13
      • Takeda: PharmaVitae forecasts at a glance
      • Strategic insight
      • Prospect of blockbuster genericization prompts wave of pipeline investment
      • Follow-on therapies vital in limiting impact of generic penetration
      • SWOT analysis
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
    • CHAPTER 3 QUARTERLY NEWS UPDATE
      • Product developments
      • Deals and alliances
      • M&A activity
      • Company announcements
      • Future product milestones
    • CHAPTER 4 COMPANY INTRODUCTION
      • Key findings
      • Background
      • Key corporate developments
      • Consumer health
      • Joint ventures
      • M&A history
      • Acquisition of Millennium Pharmaceuticals
      • Acquisition of Paradigm Therapeutics
      • Acquisition of Syrrx
      • M&A strategy
      • Pharmaceuticals business unit structure
      • Prescription pharmaceuticals
      • Consumer healthcare (OTC)
    • CHAPTER 5 COMPANY SALES
      • Key findings
      • Prescription pharmaceutical sales and growth rate analysis, 2001-13
      • Historical analysis
      • Forecast analysis
      • Product analysis
      • Product analysis, 2001-07
      • Product analysis, 2007-13
      • Therapy area analysis
      • Therapy area analysis, 2001-07
      • Therapy area analysis, 2007-13
      • Therapy area focus, 2001-13
      • Geographic analysis
      • Geographic analysis, 2001-07
      • Geographic analysis, 2007-13
      • Geographic focus, 2001-13
      • Launch/core/expiry analysis
      • Explanation of launch/core/expiry analysis
      • Launch analysis, 2007-13
      • Core analysis, 2007-13
      • Expiry analysis, 2007-13
      • Launch/core/expiry configuration, 2007-13
      • Molecule type analysis
      • Molecule type analysis, 2001-07
      • Molecule type analysis, 2007-13
      • Externalization analysis
      • Externalization analysis, 2001-07
      • Externalization analysis, 2007-13
    • CHAPTER 6 COMPANY FINANCIALS
      • Key findings
      • Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07
      • Financial statements, 2001-07
      • Profit and loss account, 2001-07
      • Balance sheet, 2001-07
      • Operating costs and profit analysis
      • Operating costs and profit analysis, 2001-07
      • Operating cost ratio and profit margin analysis, 2001-07
      • Operating cost ratio and profit margin analysis, 2007-13
      • Operating costs and profit analysis, 2007-13
      • Return on capital employed analysis
      • Capital employed analysis, 2001-07
      • Return on capital employed (RoCE) analysis, 2001-07
      • Market capitalization analysis
      • Market capitalization analysis, 2001-07
      • Total shareholder returns analysis, 2001-07
    • CHAPTER 7 KEY PRODUCTS AND COMPETITORS
      • Key findings
    • Overview
      • Gastroenterology
      • TAK-390MR
      • Prevacid
      • Amitiza
      • Endocrine, metabolic & genetic disorders
      • Actos/ACTOplus met
      • SYR-322
      • Cardiovascular
      • Blopress/Blopress Comp
      • Oncology
      • Velcade
      • Central nervous system
      • Rozerem
    • CHAPTER 8 APPENDIX
      • R&D pipeline
      • References
      • Abbreviations
      • Exchange rates
    • TABLE OF TABLES
      • Table 1: Takeda - PharmaVitae forecasts at a glance
      • Table 2: Takeda key product developments, 2008
      • Table 3: Takeda deals and alliances, 2008
      • Table 5: Takeda M&A activity, Q1 2008
      • Table 6: Takeda company announcements, Q1 2008
      • Table 7: Takeda future product milestones, 2008-10
      • Table 8: Takeda product portfolio overview ($m), 2001-07
      • Table 9: Takeda product portfolio overview ($m), 2007-13
      • Table 10: Takeda product portfolio overview ($m), 2001-07
      • Table 11: Takeda product portfolio overview ($m), 2007-13
      • Table 12: Takeda portfolio overview by geographic region ($m), 2001-07
      • Table 13: Takeda portfolio overview by geographic region ($m), 2007-13
      • Table 14: Takeda launch portfolio overview ($m), 2007-13
      • Table 15: Takeda core portfolio overview ($m), 2007-13
      • Table 16: Takeda expiry portfolio overview ($m), 2007-13
      • Table 17: Takeda portfolio overview by molecule type ($m), 2001-07
      • Table 18: Takeda product portfolio overview by molecule type ($m), 2007-13
      • Table 19: Takeda product portfolio overview by source ($m), 2001-07
      • Table 20: Takeda product portfolio overview by source ($m), 2007-13
      • Table 21: Total Takeda sales by business unit ($m), 2001-07
      • Table 22: Takeda profit and loss account ($m), 2001-07
      • Table 23: Takeda balance sheet ($m), 2001-07
      • Table 24: Takeda operating revenue/cost analysis ($m), 2001-07
      • Table 25: Takeda operating cost ratio analysis (% of total revenues), 2001-07
      • Table 26: Takeda operating cost ratio analysis (% of total revenues), 2007-13
      • Table 27: Takeda operating revenue/cost analysis ($m), 2007-13
      • Table 28: Takeda capital employed ($m), 2001-07
      • Table 29: Takeda EBIT return on capital employed ($m), 2001-07
      • Table 30: Takeda EBIT pre-tax return/Capital employed driver analysis (%), 2001-07
      • Table 31: Takeda market capitalization ($ billion), 2001-07
      • Table 34: Takeda total shareholder returns (annual %), 2001-07
      • Table 33: Key products overview
      • Table 34: TAK-390MR: overview
      • Table 35: TAK-390MR: sales forecast ($m), 2007-13
      • Table 34: Prevacid: overview
      • Table 35: Prevacid: sales forecast ($m), 2007-13
      • Table 34: Amitiza: overview
      • Table 35: Amitiza: sales forecast ($m), 2007-13
      • Table 34: Actos: overview
      • Table 34: ACTOplus met: overview
      • Table 35: Actos: sales forecast ($m), 2007-13
      • Table 35: ACTOplus met: sales forecast ($m), 2007-13
      • Table 34: SYR-322: overview
      • Table 35: SYR-322: sales forecast ($m), 2007-13
      • Table 34: Blopress: overview
      • Table 34: Blopress Comp: overview
      • Table 35: Blopress: sales forecast ($m), 2007-13
      • Table 35: Blopress Comp: sales forecast ($m), 2007-13
      • Table 34: Velcade: overview
      • Table 35: Velcade: sales forecast ($m), 2007-13
      • Table 34: Rozerem: overview
      • Table 35: Rozerem: sales forecast ($m), 2007-13
      • Table 56: Takeda's R&D pipeline (Phase I-registration)
      • Table 38: Exchange rates, 2007
    • TABLE OF FIGURES
      • Figure 1: Takeda prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
      • Figure 2: Takeda's financial performance ($m), 2001-13
      • Figure 3: Takeda SWOT analysis
      • Figure 7: Pharmaceuticals business unit structure
      • Figure 8: Takeda prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
      • Figure 9: Takeda key sales growth driver & resistors ($m), 2001-07
      • Figure 10: Takeda key sales growth drivers & resistors ($m), 2007-13
      • Figure 11: Takeda prescription pharmaceutical sales by therapy area ($m), 2001-13
      • Figure 12: Takeda prescription pharma sales by therapy area (% of total), 2001-13
      • Figure 13: Takeda prescription pharmaceutical sales by geographic region ($m), 2001-13
      • Figure 15: Takeda drivers and resistors by geographic region ($m), 2007-13
      • Figure 16: Takeda prescription pharmaceutical sales by geographic region (% of total), 2001-13
      • Figure 17: Takeda launch/core/expiry configuration ($m), 2007-13
      • Figure 18: Takeda prescription pharmaceutical sales by molecule type ($m), 2001-13
      • Figure 20: Takeda prescription pharmaceutical sales by source ($m), 2001-13
      • Figure 22: Takeda growth drivers and resistors by source ($m), 2007-13
      • Figure 23: Takeda operating revenue/cost analysis ($m), 2001-13
      • Figure 24: Takeda operating cost ratio analysis (% of total revenues), 2001-13
      • Figure 25: Takeda return on capital employed, EBIT margin and capital turnover, 2001-07
      • Figure 26: Return on capital employed formula
      • Figure 27: Takeda market capitalization ($ billion), 2001-07
      • Figure 28: Takeda total shareholder returns vs. S&P 500 ($m), 2001-07
      • Figure 27: Takeda's upper GI franchise, sales ($m), 2007-13